Fitzgerald Joseph Michael, EVP & Group President of Cardiology at Boston Scientific (BSX), has demonstrated a clear selling bias in his recent insider transactions, with no open-market purchases recorded in the past year. Since August 2025, Fitzgerald has executed a series of sales totaling approximately $42.6 million against $7.5 million in total buy value across 68 transactions—all concentrated in BSX. His most significant disposals include a $5.2 million sale on August 1, 2025, followed by multiple seven-figure transactions in September ($5.3 million combined) and October ($4.9 million). The pattern intensified in November 2025 with three sales worth nearly $5 million, including a single $2.9 million transaction on November 3.
More recently, Fitzgerald’s activity shifted to smaller but consistent sales in February 2026, totaling over $2.9 million across four transactions, with the largest being a $2.47 million sale on February 13. Notably, these disposals were classified as "F" (tax liability) or "M" (exercise of derivative security) transactions, suggesting they may relate to option exercises or tax obligations rather than discretionary trades. The absence of any recent buys, coupled with the sustained selling trend, indicates a reduction in his BSX position over time. All transactions occurred under prearranged trading plans, as indicated by Rule 10b5-1 codes in the filings.
AI-assisted summary